# Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

> **NCT04993365** · PHASE4 · COMPLETED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 520 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Experimental Group
- **BIOLOGICAL:** Control Group

## Key facts

- **NCT ID:** NCT04993365
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-05
- **Primary completion:** 2022-07-14
- **Final completion:** 2022-07-14
- **Target enrollment:** 520 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993365, "Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04993365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*